Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 for GVHD Prophylaxis After Allogeneic HSCT
NCT00539695Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2007
- Primary completion
- Apr 2013
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in graft-versus-host disease (GVHD), sponsored by Baylor College of Medicine. Started Jun 2007; status: completed.
02
Drugs
aldesleukin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00539695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539695.